Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment

Clinical and Translational Oncology

Volumn 9, Issue 9, 2007, Pages 578-581

  Grande, C ^a   Villanueva, M J ^a   Huidobro, G ^a   Casal, J ^a  

^a UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

Author keywords

Docetaxel; Interstitial pneumonitis; Non small cell lung cancer

Indexed keywords

DOCETAXEL; GEMCITABINE; ANTINEOPLASTIC AGENT; TAXOID;

BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG FATALITY; DRUG INDICATION; DRUG WITHDRAWAL; HUMAN; INTERSTITIAL PNEUMONIA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RADIATION DOSE; REVIEW; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; INTERSTITIAL LUNG DISEASE; LUNG TUMOR;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 38449109340     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0106-4     Document Type: Review

References (29)

1. Stover DE, Kaner JR (2005) Pulmonary toxicity. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer principles and practice of oncology, 7th Edn. Lippincott Williams and Wilkins, Philadelphia, pp 2535-2545
2. (2006) Interstitial pneumonia in Taxotere. In: Micromedex. Healthcare series. Available at: http://www.micromedex.com
3. (2006) Taxane-induced pulmonary toxicity. UptoDate version 14.3. Available at: http://www.uptodate.com
4. Karakan O, Eyuboglu FO, Akcay S, Ozylkan O (2004) Acute interstitial pneumopathy associated with docetaxel hypersensitivity. Onkologie 27:563-565
5. Karasawa K, Katsui K, Seki K et al (2003) Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer. Breast Cancer 10:268-274
6. Behrens RJ, Gulley JL, Dahut WL (2003) Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. Am J Ther 10:228-232
7. Dunsford ML, Mead GM, Bateman AC et al (1999) Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 10:943-947
8. Read WL, Mortimer JE, Picus J (2002) Severe interstitial pneumonitis associated with docetaxel administration. Cancer 94:847-853
9. Etienne B, Perol M, Nesme P et al (1998) Acute diffuse interstitial pneumopathy following docetaxel. A propos of 2 cases. Rev Mal Respir 15:199-203
10. Wang GS, Yang KY, Perng RP (2001) Life-threatening hypersensitivity pneumonitis induced by docetaxel. Br J Cancer 85:1247-1250
11. Chen YM, Shih JF, Lee CS et al (2003) Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small cell lung cancer patients failing previous chemotherapy with or without paclitaxel. Lung Cancer 39:209-214
12. Hainsworth JD, Burris HA, Greco FA (2001) Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancer. Semin Oncol 28:21-25
13. Chen YM, Perg RP, Lin WC et al (2002) Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small cell lung cancer patients failing previous chemotherapy. Am J Clin Oncol 25:509-512
14. Kouroussis C, Mavroudis D, Kakolyris S et al (2004) High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: Results of a dose-finding study. Lung Cancer 44:363-368
15. Fernández Y, Esteban E, Villanueva J et al (2006) Prospective randomised phase II study of gemcitabine and vinorelbine versus gemcitabine and docetaxel combination in patients with previously untreated advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 671:17052
16. McNeill G, Kalmadi S, Davis M et al (2006) Phase II trial of weekly docetaxel and gemcitabine as first line therapy for patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 673:17076
17. Popa IE, Stewart K, Smith FP, Rizvi NA (2002) A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive advanced non-small cell lung carcinoma. Cancer 95:1714-1719
18. Onishi H, Kuriyama K, Yamaguchi M et al (2003) Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: A good local response but no good survival due to radiation pneumonitis. Lung Cancer 40:79-84
19. Vergnenegre A, Daniel C, Lena H et al (2005) Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small cell lung cancer. Lung Cancer 47:395-404
20. Jang TW, Park JP, Kim HK et al (2004) Concurrent docetaxel-cisplatin and thoracic radiotherapy for locally advanced non-small cell lung cancer. Tuberc Respir Dis 57:257-264
21. Sakai H, Yoneda S, Kobayashi K et al (2004) Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III non-small cell lung cancer. Lung Cancer 43:195-201
22. Bedano PM, Neubauer M, Ansari R et al (2006) Phase III study of cisplatin plus etoposide with concurrent chest radiation followed by docetaxel vs. observation in patients with stage III non-small cell lung cancer: An interim toxicity analysis of consolidation therapy. Proc Am Soc Clin Oncol 374:7043
23. Gandara DR, Chansky K, Albain KS et al (2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage III non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004-2010
24. Sekine I, Nokihara H, Sumi M et al (2006) Docetaxel consolidation therapy following cisplatin, vinorelbine and concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J Thorac Oncol 8:810-815
25. Moon C, Verschraegen CF, Bevers M et al (2000) Use of docetaxel in patients with paclitaxel hypersensitivity. Anticancer Drugs 11:565
26. Denman JP, Gilbar PJ, Abdi EA (2002) Hypersensitivity reaction to docetaxel after a previous hypersensitivity reaction to paclitaxel. J Clin Oncol 20:2760
27. Chen YM, Shif JF, Perng RP et al (2006) A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 129:1031-1038
28. (2006) Radiation-induced lung injury. UptoDate, version 14.3. Available at http://www.uptodate.com
29. Villanueva N, Esteban E, Muñiz I et al (2006) Weekly 70 Gy thoracic radiotherapy concurrent with docetaxel or paclitaxel alter induction chemotherapy of patients with locally advanced non-small cell lung cancer. Prospective study of tolerance and efficacy. Oncología 29:30-36